Quick Answer
C4 Therapeutics, Inc. reported Operating Income of -$115.22 million for fiscal year 2025.
C4 Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$115.22M | +3.7% |
| 2024 | -$119.61M | +14.0% |
| 2023 | -$139.03M | -7.3% |
| 2022 | -$129.53M | -57.7% |
| 2021 | -$82.13M | -35.9% |
| 2020 | -$60.45M | -70.5% |
| 2019 | -$35.45M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.41M | -21.8% | -20.7% |
| June 30, 2025 | -$28.50M | -32.9% | +2.3% |
| March 31, 2025 | -$29.16M | +9.5% | -3.3% |
| September 30, 2024 | -$28.24M | -1.6% | -31.7% |
| June 30, 2024 | -$21.44M | +42.9% | +33.4% |
| March 31, 2024 | -$32.22M | +11.1% | -15.9% |
| September 30, 2023 | -$27.81M | +14.4% | +26.0% |
| June 30, 2023 | -$37.57M | -37.2% | -3.7% |
- C4 Therapeutics, Inc. showed an increase of +3.7% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, C4 Therapeutics, Inc.’s operating income has declined by 225.0% (from -$35.45 million to -$115.22 million).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: